Carol Burt

Five Nasdaq-listed companies appear in Carol Burt's 43 filings, published between May 4, 2016 and April 27, 2026, all as a Director: ResMed Inc (21), Wellcare Health Plans, Inc. (7), Iqvia Holdings Inc. (6), Envision Healthcare Corp (6) and Envision Healthcare Holdings, Inc. (3).

The 6 sales come to EUR 2.6 million, with a median of EUR 280,943; 3 are at ResMed and 3 at Wellcare. The largest is dated March 2, 2020 at ResMed (EUR 1,492,131), followed by one on November 22, 2021 (EUR 345,875) and, at Wellcare, one on May 8, 2017 (EUR 280,947). No purchase is recorded. The rest is 24 grants, 3 option exercises and 10 other lines.

The year 2017 counts 8 filings, 2016 and 2021 count 6 each, then the pace drops to 1 a year in 2025 and 2026. Two filings fall in the last twelve months, with no sale. The publication delay is a median of 2 days.

3, 3 and 3 trades by Burt fall within 30 days of colleagues at ResMed Inc, in that order. All of them in the same direction. In the same order, the colleagues are Brett Sandercock, David Pendarvis and James Hollingshead.